Fresenius Kabi Acquires Ivenix For $240M To Expand Presence In Infusion Pump Market
Fresenius Kabi will pay up to $240m for Massachusetts-based Invenix to expand its infusion pump portfolio. Simultaneously, the company also made a major move to bolster its biosimilars business by acquiring a majority stake in mAbxience.
You may also be interested in...
Fresenius Brings In Transparency Change For Kabi Unit
Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.
Fresenius Kabi Takes Control Of mAbxience To Bolster Biosimilars
Fresenius Kabi has made a major move to bolster its biosimilars business by acquiring a majority 55% stake in mAbxience, with the purchase price comprising €495m upfront as well as subsequent milestone payments. The deal offers Fresenius not only enhanced biosimilars capabilities but also access to the expanding biologics CDMO market.
Fresenius Puts Kabi At The Top As It Ponders Best Use Of Cash
The Fresenius group has all but ruled out any equity investment in Fresenius Kabi, as it looks to make the best use of its capital and “tap new capital sources” to drive growth.